Verrica Pharms Drug Patent Portfolio
Verrica Pharms owns 1 orange book drug protected by 2 US patents Given below is the list of Verrica Pharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11147790 | Treatment of cutaneous disorders | 22 Aug, 2038 | Active |
US11052064 | Compositions, methods and systems for the treatment of cutaneous disorders | 28 May, 2035 | Active |
Latest Legal Activities on Verrica Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Verrica Pharms.
Activity | Date | Patent Number |
---|---|---|
Second letter to regulating agency to determine regulatory review period | 07 Mar, 2024 | US11052064 |
Letter from FDA or Dept of Agriculture re PTE application | 07 Feb, 2024 | US11052064 |
Initial letter Re: PTE Application to regulating agency | 06 Dec, 2023 | US11052064 |
Patent Term Extension Application under 35 USC 156 Filed | 12 Sep, 2023 | US11052064 |
Recordation of Patent Grant Mailed
Critical
| 19 Oct, 2021 | US11147790 |
Patent Issue Date Used in PTA Calculation
Critical
| 19 Oct, 2021 | US11147790 |
Email Notification
Critical
| 30 Sep, 2021 | US11147790 |
Issue Notification Mailed
Critical
| 29 Sep, 2021 | US11147790 |
Dispatch to FDC | 22 Sep, 2021 | US11147790 |
Application Is Considered Ready for Issue
Critical
| 22 Sep, 2021 | US11147790 |
Filing Receipt - Corrected | 15 Sep, 2021 | US11147790 |
Email Notification
Critical
| 15 Sep, 2021 | US11147790 |
Issue Fee Payment Verified
Critical
| 10 Sep, 2021 | US11147790 |
Issue Fee Payment Received
Critical
| 10 Sep, 2021 | US11147790 |
Electronic Review
Critical
| 09 Sep, 2021 | US11147790 |
Verrica Pharms's Family Patents
Verrica Pharms Drug List
Given below is the complete list of Verrica Pharms's drugs and the patents protecting them.
1. Ycanth
Ycanth is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11147790 | Treatment of cutaneous disorders |
22 Aug, 2038
(13 years from now)
| Active |
US11052064 | Compositions, methods and systems for the treatment of cutaneous disorders |
28 May, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ycanth's drug page